findmyKOL

Vikram Gorantla

Basic profile

University of Pittsburgh

ORCIDNone on fileNPI
RegionPittsburgh, PA · NortheastSpecialtyHematology / OncologyFocusOncology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Vikram Gorantla is an Oncology physician affiliated with University of Pittsburgh. OpenAlex indexes 68 publications with 370 citations (h-index 11).

Overview

Scholarship

indexed output and impact (OpenAlex)
68publications

Distinct works indexed by OpenAlex.

370citations

Total citations across indexed works.

11h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
18companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

18 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    61.7%
    Aromatase Inhibitor53%
    Anastrozole68%Letrozole23%Exemestane9%
    Part D113 patients
    Estrogen Agonist/Antagonist6%
    Tamoxifen Citrate100%
    Part D19 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    19.6%
    Serotonin-3 Receptor Antagonist9.3%
    Ondansetron Hcl100%
    Part D57 patients
    Antidiarrheal microorganisms3.2%
    Creon100%
    Part D14 patients

    + 3 more classes in this area

  • Nervous system

    11.6%
    Phenothiazine10.3%
    Prochlorperazine Maleate100%
    Part D53 patients
    Gabapentinoids1.3%
    Gabapentin100%
    Part D<11 patients
Where care is delivered (Part B)56.3% facility · 43.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”